Search
for

    Research

    5 / 1000+ results

    Community Join

    5 / 1000+ results

      community Has anyone used the new liposomal topical fin from Hasson and Wong?

       6 upvotes 10 years ago
      The conversation discusses a new liposomal topical finasteride from Hasson and Wong, available in Canada and Italy, soon in the US, costing $40/month. It claims to reduce scalp DHT by 50% without affecting serum DHT, potentially benefiting those who can't tolerate oral finasteride or RU58841.
      The story of RU58841/ PSK3841

      community The story of RU58841/ PSK3841

      in Research  622 upvotes 1 year ago
      RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.

      community The story of RU58841/PSK3841

      in Research/Science 1 year ago
      RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

      community Concerns about CosmeRNA safety mechanisms

      in Treatment  3 upvotes 3 years ago
      Concerns about CosmeRNA safety mechanisms and potential side effects. Discussion includes comparisons to Fluridil and questions about nanoparticle specificity and siRNA stability.